Efeitos na força muscular respiratória, capacidade funcional cardiorrespiratória e qualidade de vida de pacientes com DPOC submetidos a dois diferentes equipamentos de treinamento muscular respiratório
Data
2019-04-12
Autores
Oliveira, Kelly Cristina da Silva
Título da Revista
ISSN da Revista
Título de Volume
Editor
Universidade Estadual Paulista (Unesp)
Resumo
A Doença Pulmonar Obstrutiva Crônica (DPOC) traz, como uma de suas consequências, a fraqueza muscular respiratória. Tal complicação acarreta em menor capacidade funcional cardiorrespiratória e pior qualidade de vida. No entanto, o treinamento muscular respiratório (TMR) tem se mostrado benéfico para minimizar esses prejuízos. O objetivo deste estudo foi avaliar os efeitos na força muscular respiratória, capacidade funcional cardiorrespiratória e qualidade de vida de indivíduos com DPOC submetidos a dois diferentes equipamentos de TMR. Dezessete indivíduos foram avaliados por meio da espirometria para confirmação da obstrução e estadiamento da doença. Foram submetidos à avaliação de manovacuometria para verificar a força muscular respiratória, teste de caminhada de seis minutos (TC6) para obter a capacidade funcional cardiorrespiratória e responderam ao questionário do Hospital Saint George na Doença Respiratória (SGRQ) para avaliação da qualidade de vida. Os indivíduos foram divididos em dois grupos para realização de TMR durante quatro semanas, um com o uso do Threshold® IMT (GIMT) e outro do POWERbreathe® Classic (GP). Houve aumento significativo da força muscular respiratória, com aumento da pressão inspiratória máxima de -62±16,03 para -75,55±22,84 cmH2O no GIMT, e de -56±22,01 para -71,25±27,67 cmH2O no GP. No TC6 houve aumento clínico da distância percorrida tanto no GIMT de 404,22±139,58 m para 437,77±137,30 m, quanto no GP de 408,75 m (360,75 - 514,00) para 439,50 m (406,50 - 540,00). Quanto ao SGRQ houve melhora nos domínios atividade (66,40±23,85 para 55,94±22,51% no GIMT e de 68,72±23,41 para 59,62±24,86% no GP), impacto (43,30±27,93 para 30,30±21,11% no GIMT e de 49,16±21,76 para 36,68±22,39 no GP) e no escore total (50,85±25,28 para 41,54±20,96% no GIMT e de 55,23±18,85 para 44,94±19,53% no GP). Foi considerada diferença estatisticamente significativa p< 0,05. Para os resultados intergrupos, não houve diferença estatisticamente significativa para força muscular respiratória, distância percorrida no TC6 e qualidade de vida. Foi possível concluir que ambos os equipamentos trazem desfechos positivos e semelhantes nos indivíduos com DPOC, não evidenciando superioridade de um sobre o outro para as variáveis analisadas.
Chronic obstructive pulmonary disease (COPD) has as one of its consequences, respiratory muscle weakness. Such complication results in lower cardiorespiratory functional capacity and worse quality of life. However, respiratory muscle training (RMT) promotes beneficial for these loses. The aim of this study was to evaluate the effects on respiratory muscle strength, cardiorespiratory functional capacity and quality of life of individuals with COPD submitted to two different TMR equipments. Seventeen individuals were evaluated by spirometry for confirmation of blocking and staging of the disease. They were submitted to manovacuometria assessment to verify the respiratory muscle strength, six-minute walk test (6MWT) to obtain a cardiorespiratory functional capacity and to fill the questionnaire Saint George Hospital in Respiratory Disease (SGRQ) to evaluate the quality of life. Individuals were divided in two groups for four weeks for to execute the RMT, one using Threshold® IMT (GIMT) and another using POWERBreathe® Classic (GP). There was a significant increase in respiratory muscle strength, with maximal inspiratory pressure increasing from -62 ± 16.03 to -75.55 ± 22.84 cmH2O in the GIMT, and from -56 ± 22.01 to -71, 25 ± 27.67 cmH2O in GP. In the 6MWT, there was a clinical increase of the walked distance in the GITM from 404.22 ± 139.58 m to 437.77 ± 137.30 m, and in the GP from 408.75 m (360.75 - 514.00) to 439, 50 m (406.50 - 540.00). In SGRQ, there was an improvement in the activity domains (66.40 ± 23.85 for 55.94 ± 22.51% in the GIMT and 68.72 ± 23.41 for the 59.62 ± 24.86% in the GP), impact (43.30 ± 27.93 for 30.30 ± 21.11% in the GIMT and 49.16 ± 21.76 for 36.68 ± 22.39% in the GP) and in the total score (50.85 ± 25, 28 to 41.54 ± 20.96% in the IMTG and 55.23 ± 18.85 to 44.94 ± 19.53% in the GP). A statistically significant difference was considered p <0.05. For the intergroup results, there was no statistically significant difference for respiratory muscle strength, distance walked on the 6MWT and quality of life. It was possible to conclude that both devices had positive and similar outcomes in individuals with COPD, showing no superiority of one over the other for the variables analyzed.
Chronic obstructive pulmonary disease (COPD) has as one of its consequences, respiratory muscle weakness. Such complication results in lower cardiorespiratory functional capacity and worse quality of life. However, respiratory muscle training (RMT) promotes beneficial for these loses. The aim of this study was to evaluate the effects on respiratory muscle strength, cardiorespiratory functional capacity and quality of life of individuals with COPD submitted to two different TMR equipments. Seventeen individuals were evaluated by spirometry for confirmation of blocking and staging of the disease. They were submitted to manovacuometria assessment to verify the respiratory muscle strength, six-minute walk test (6MWT) to obtain a cardiorespiratory functional capacity and to fill the questionnaire Saint George Hospital in Respiratory Disease (SGRQ) to evaluate the quality of life. Individuals were divided in two groups for four weeks for to execute the RMT, one using Threshold® IMT (GIMT) and another using POWERBreathe® Classic (GP). There was a significant increase in respiratory muscle strength, with maximal inspiratory pressure increasing from -62 ± 16.03 to -75.55 ± 22.84 cmH2O in the GIMT, and from -56 ± 22.01 to -71, 25 ± 27.67 cmH2O in GP. In the 6MWT, there was a clinical increase of the walked distance in the GITM from 404.22 ± 139.58 m to 437.77 ± 137.30 m, and in the GP from 408.75 m (360.75 - 514.00) to 439, 50 m (406.50 - 540.00). In SGRQ, there was an improvement in the activity domains (66.40 ± 23.85 for 55.94 ± 22.51% in the GIMT and 68.72 ± 23.41 for the 59.62 ± 24.86% in the GP), impact (43.30 ± 27.93 for 30.30 ± 21.11% in the GIMT and 49.16 ± 21.76 for 36.68 ± 22.39% in the GP) and in the total score (50.85 ± 25, 28 to 41.54 ± 20.96% in the IMTG and 55.23 ± 18.85 to 44.94 ± 19.53% in the GP). A statistically significant difference was considered p <0.05. For the intergroup results, there was no statistically significant difference for respiratory muscle strength, distance walked on the 6MWT and quality of life. It was possible to conclude that both devices had positive and similar outcomes in individuals with COPD, showing no superiority of one over the other for the variables analyzed.
Descrição
Palavras-chave
DPOC, Força muscular respiratória, Capacidade funcional cardiorrespiratória, Qualidade de vida, Treinamento muscular respiratório, COPD, Respiratory muscle strength, Functional cardiorespiratory capacity, Quality of life, Respiratory muscle training